Mutación de resistencia ALK G1202R
Vista determinista de la entidad fuente YAML. La autoridad clínica sigue con los ID de fuente citados y estado de firma del revisor.
| ID | BIO-ALK-G1202R |
|---|---|
| Tipo | Biomarcador |
| Aliaces | ALK G1202R — мутація резистентностіALK p.G1202RMutación delantera con disolvente ALK |
| Situación | reviewed 2026-04-27 | pending_clinical_signoff |
| Enfermedades | DIS-IMT |
| Fuentes | SRC-CROWN-SOLOMON-2021 SRC-ESMO-NSCLC-METASTATIC-2024 SRC-NCCN-NSCLC-2025 |
Datos sobre biomarcadores
| Tipo de biomarcador | gene_mutation |
|---|---|
| Detalles de la mutación | {"exón": "23", "functional_impact":"pan-ALK-TKI resistencia (crizotinib, ceritinib), alectinib y brigatinib; mantiene sensibilidad a lorlatinib", "gene":", "ALK", "hgvs_protein": «p.G1202R", "variant_type": „misense"} |
| Medición | MétodoctDNA NGS (preferred at TKI progression) OR repeat tumor biopsy NGS; targeted ALK-resistance panels acceptable Unidadescategorical (positive | negative); VAF % when reported Requisito de sensibilidadFAV ≥0,5% (ADN cf) administrado típicamente de emergencia subclonal |
| Consulta de la capacidad de acción | {"gen": "ALK", "variante":"G1202R"} |
| Productos químicos y químicos | BIO-ALK-FUSION BIO-ALK-REARRANGEMENT BIO-ALK-L1196M |
Notas
Most common on-target ALK-resistance mutation after 2nd-generation TKI (alectinib, brigatinib): emerges in ~20-40% of post-2G-TKI re-biopsies. Solvent-front position blocks binding of 1st/2nd-gen ALK inhibitors. Lorlatinib (3rd-gen, macrocyclic) maintains activity per CROWN trial data and post-progression analyses; preferred 2L+ option when G1202R detected. Compound mutations (G1202R + L1196M, G1202R + I1171N, etc.) may emerge under lorlatinib pressure and confer pan-ALK-TKI resistance — trial enrollment indicated.
Utilizado por
Biomarcador
BIO-ALK-L1196M- ALK L1196M mutación de resistencia del portero
Señal de alerta
RF-IMT-TRANSFORMATION-PROGRESSION- IMT progression on first-line crizotinib (acquired ALK kinase-domain resistance mutation...